Gordon Yale, CPA, CFF, CFE Expert Witness
Curriculum Vitae


Contact this Expert Witness

  • Company: Yale Forensics
  • Phone: 303-355-6087
  • Cell: 303-886-4725
  • Fax: 303-355-7307
  • Website: gyale.com

Specialties & Experience of this Expert Witness

General Specialties:

Securities & Investments and Accounting

Keywords/Search Terms:

Adequacy of disclosure in securities offerings , adequacy of due diligence by brokers and investment advisers, accounting and audit negligence, private placement of securities, real estate investments, fixed income securities, Ponzi schemes, financial analysis, life settlements, securities fraud.


Bachelor of Arts, University of Colorado; Master of Accountancy, University of Denver

Years in Practice:


Number of Times Deposed/Testified in Last 4 Yrs:


Additional Information

I have testified in state and federal courts, SEC administrative hearings, FINRA and private arbitrations. Cases have included multi-billion Ponzi schemes including Medical Capital Secured Notes, Provident Royalties Preferred Stock, DBSI Housing TICs, Notes, and various land funds, IMH Secured Loan Funds, Discovery Oil, InterBank Funding Income Fixed Rate Participating Notes, Dallas Proton Treatment Center, LLC Convertible Notes and other investments including partnerships, privately offered REITs. I have conducted three investigations of Big 4 accounting firms in connection with their audits of thrift institutions, including Silverado Saving and Loan, for the Colorado Board of Accountancy, done municipal bond valuations for the state of Hawaii and served as an expert for the state of Florida in its action against Angelo Mozilo, the co-founder and former CEO of Countrywide Financial Corporation. I have owned a securities broker-dealer, worked as an investment banker and fixed income analyst and testified in federal court on damages related to patent infringements and adequacy of disclosure in tax-exempt bond documents. I have testified in SEC administrative hearings involving audit negligence as well as financial reporting fraud by officers of a publicly held pharmaceutical company. I have testified on the accuracy of disclosure in a life insurance premium financing scheme and have been engaged twice in matters involving life settlements. In addition, I have had articles published by the Financial Executives International Research Foundation, the Professional Officers' and Directors' Liability and Law Committee Newsletter of the American Bar Association, and other professional journals and newsletters. The topics have included the cannibalization of accounting for equity participation notes and troubled loan accounting, how special purpose entities were abused by Enron and the tangled accounting for mortgage-backed securitizations.